scispace - formally typeset
E

Elizabeth Galbreath

Researcher at Eli Lilly and Company

Publications -  20
Citations -  2822

Elizabeth Galbreath is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: T cell & Sepsis. The author has an hindex of 11, co-authored 18 publications receiving 2578 citations.

Papers
More filters
Journal ArticleDOI

FGF-21 as a novel metabolic regulator

TL;DR: It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Journal ArticleDOI

Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor.

TL;DR: It is proposed that adipsin is a Hes-1-regulated gene that is de-repressed during FGSI-mediated disruption of Notch/Hes-1 signaling, and its presence in feces may serve as a noninvasive biomarker of gastrointestinal toxicity associated with perturbed Notch signaling.
Journal ArticleDOI

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

TL;DR: Unexpected inhibition of PKCβ in vivo led to decreased VEGF production that persisted after therapy as well as to decreased intratumoral vessels.
Journal ArticleDOI

Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions.

TL;DR: Tissue cross-reactivity studies are screening assays recommended for antibody and antibody-like molecules that contain a complementarity-determining region (CDR), primarily to identify off- target binding and, secondarily, to identify sites of on-target binding that were not previously identified.